NASDAQ: FULCFulcrum Therapeutics Inc Stock
$3.29+0.23 (+7.52%)
Updated Apr 17, 2025
FULC Price
$3.29
Fair Value Price
N/A
Market Cap
$177.59M
52 Week Low
$2.32
52 Week High
$10.13
P/E
-20.56x
P/B
0.73x
P/S
3.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$80.00M
Earnings
-$9.73M
Gross Margin
100%
Operating Margin
-12.16%
Profit Margin
-12.2%
Debt to Equity
0.07
Operating Cash Flow
-$2M
Beta
1.24
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
FULC Overview
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FULC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FULC
Ranked#234 of 463
Ranked#234 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important FULC news, forecast changes, insider trades & much more!
FULC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FULC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FULC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FULC is good value based on its book value relative to its share price (0.73x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
FULC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FULC due diligence checks available for Premium users.
Valuation
FULC fair value
Fair Value of FULC stock based on Discounted Cash Flow (DCF)
Price
$3.29
Fair Value
$0.03
Overvalued by
12,853.68%
FULC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FULC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-20.56x
Industry
-177.72x
Market
27.98x
FULC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.73x
Industry
4.05x
FULC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FULC's financial health
Profit margin
Revenue
$0.0
Net Income
-$16.6M
Profit Margin
0%
FULC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
FULC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$260.7M
Liabilities
$17.7M
Debt to equity
0.07
FULC's short-term assets ($249.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FULC's short-term assets ($249.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FULC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FULC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
$2.3M
Financing
$83.0k
FULC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FULC vs Biotech Stocks
Fulcrum Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.